About us

Almirall is a global pharmaceutical company dedicated to medical dermatology, based in Barcelona. We collaborate closely with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform patients' lives by helping them realise their hopes and aspirations for a healthy life. We are at the forefront of science, delivering ground-breaking and differentiated medical dermatology innovations that address patients´ unmet needs.

This is Almirall's legacy for future generations, it is our contribution to society

See our purpose video

At a glance

Last updated: May / 2024

Global presence

2,027total number of employees

14affiliates in the EU and the US

100+countries

€985.7million net sale

12.6%of net sales invested in R&D

40nationalities

Some of our major milestones

1944Foundation of Laboratory Almirall, S.A.

1960Almirall begins its research and development activities.

1984Launch of the antacid almagate in Spain.

19901990 Launch of the antihistamine ebastine in Spain and granting of licences at an international scale.

1997Creation of Laboratorios Almirall Prodesfarma, S.A., following the merger of Grupo Almirall, S.A. and Grupo Prodesfarma.

2007Almirall acquires Hermal, a European prescription dermatology business of Reckitt Benckiser.

2012The European Medicines Agency (EMA) approves the commercialisation of aclidinium for the treatment of chronic obstructive pulmonary disease (COPD) in Europe, marketed as Eklira® Genuair® and Bretaris® Genuair®.

2013Almirall reaches an agreement to acquire Aqua Pharmaceuticals, a US‑based specialty dermatology company.

2014Almirall transfers to AstraZeneca the rights to its respiratory franchise, including development and commercialisation activities, partnership-related revenues, and its investigational pipeline in respiratory diseases.

2015Acquisition of Poli Group, a pharmaceutical company specialising in dermatology and a global leader in nail diseases, including onychomycosis, nail psoriasis, and nail dystrophy, as well as skin mycoses, rosacea, and acne.

2016Almirall and Sun Pharmaceutical Industries Ltd. sign a licensing agreement for the development and commercialisation of tildrakizumab in Europe, a biologic treatment for patients with moderate‑to‑severe plaque psoriasis.

2018In August, Almirall enters into an agreement to acquire five products from Allergan’s US medical dermatology portfolio for acne and dermatoses. The portfolio includes Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid), Cordran® Tape (fludroxycortide), and Seysara® (sarecycline).